HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Genmab (NASDAQ:GMAB) and maintained a price target of $50.
October 16, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Genmab and maintained a $50 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $50 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Genmab's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100